Gene Therapy and Rare Diseases

Manufacturing Expertise

Paragon Gene Therapy has the privilege to work with biotech, academic, government and pharmaceutical companies that are utilizing the latest technologies in cell and gene therapy. We are dedicated to our clients and help develop their methods into a scalable and commercially viable process.

Whether is it insect, transient mammalian, or virus-mediated rAAV production, we have experience scaling-up and developing a process tailored towards our client’s bottom line. Your technology is not cookie-cutter; why should your manufacturing process be?

Targeted Therapies

There are currently over 70 rAAV candidates in late-stage development

Key Technologies

Manufacturing yields >10E5 viral genome particles per cell further boosting feasibility

Over the years, we have helped our clients move from an adherent culture into a scalable, suspension-based process utilizing serum-free/animal-free components. (Serotypes 1, 2, 5, 6, 8, 9, & 10). 

We are industry experts in the standard manufacturing practices for the rAAV including transient mammalian, baculovirus, and HSV.

>75% of our current contracts are for Gene Therapy

There is a strong global demand for rAAV manufacturing and only limited by capacity